Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Summary
This is a multicenter, open-label phase I/II study for participants with advanced solid tumors who have failed prior immune checkpoint inhibitor therapies.
Official title: A Study to Evaluate the Efficacy and Safety of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
153
Start Date
2025-09
Completion Date
2027-12
Last Updated
2025-08-27
Healthy Volunteers
No
Conditions
Interventions
ZG005
ZG005 20mg/kg; once every 3 weeks；IV infusion
Gecacitinib
Gecacitinib for dose escalations are set as 100mg Bid po. Gecacitinib for dose expansion will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.
Locations (1)
Chinese PLA General Hosptial
Beijing, Beijing Municipality, China